Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

163.91 +0.51 (+0.31%)
Streaming Delayed Price Updated: 11:58 AM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Pain Relief Medication Market to Witness Huge Growth by Key Players: Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Plc.
Global Pain Relief Medication Market By Material (Acute, Chronic), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) 
Via SBWire
This Could Cost Johnson & Johnson Billions in Profit
The talc lawsuits create some risk for the business -- but is it enough of a reason to stay away from the stock? 
Via The Motley Fool
3 Dividend Stocks That Will Hold Up No Matter the Market Conditions
These stocks could boost your portfolio in bear markets and bull markets. 
Via The Motley Fool
Is It Time to Buy the Dow Jones' 3 Worst-Performing January Stocks?
They aren't quite the Dogs of the Dow, but these blue chips are limping into February. 
Via The Motley Fool
The 3 Best Forever Stocks to Buy for February 2023
These forever stocks are established companies with great track records that can weather the ups and downs of the market and the economy. 
Via InvestorPlace
2 Reasons to Buy Johnson & Johnson, and 2 Reasons to Sell
If you're interested in a passive income stock, it's among the most reliable. 
Via The Motley Fool
1 Resilient Blue Chip Stock to Buy on the Dip
You don't stay in business for decades unless you are doing something right. 
Via The Motley Fool
2 Stocks Down More Than 6% to Buy Right Now
These companies outperformed the market last year. 
Via The Motley Fool
Johnson & Johnson's Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder
 
Via Benzinga
Why Is Catalent (NYSE:CTLT) Stock Up 20% Today?
Catalent (CTLT) stock is soaring more than 20% in early trading on a report that Danaher was interested in buying CTLT. 
Via InvestorPlace
Johnson & Johnson's Latest Talcum Powder Development Could Be Costly
Johnson & Johnson's pockets could become billions lighter. 
Via The Motley Fool
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
Danaher Corporation (NYSE: DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE: CTLT). 
Via Benzinga
3 Unstoppable Dividend Stocks to Buy in February
All three belong to the elite group of stocks known as Dividend Kings. 
Via The Motley Fool
MarketBeat Week in Review – 1/30 - 2/3
The markets are trending lower to end the week. It’s hard to figure out the markets after the blockbuster job report, but the MarketBeat team gave it a shot 
Via MarketBeat
Topics Artificial Intelligence Earnings Economy
Exposures Artificial Intelligence Financial Interest Rates
3 Dow Stocks That Make for Screaming Buys in February
Out of the Dow Jones Industrial Average's 30 components, there are three amazing deals hiding in plain sight. 
Via The Motley Fool
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
From Johnson & Johnson
Via Business Wire
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG 
Via SBWire
Exposures COVID-19
Johnson & Johnson's Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
 
Via Benzinga
3 Defensive Stocks to Buy If You Think the Market Is Headed Lower
For those concerned about the potential for the market to decline further, these defensive stocks certainly have your back right now. 
Via InvestorPlace
Looking for a Reliable Dividend Payer? Consider Buying This Blue-Chip Stock
This company has the most impressive dividend growth streak in the entire healthcare sector. 
Via The Motley Fool
3 Dividend Stocks to Buy in 2023 for a Lifetime of Passive Income
If you buy these passive-income machines now, you could build a fortune. 
Via The Motley Fool
Is Johnson & Johnson Stock Worth Buying on the Dip?
The healthcare giant's stock is facing headwinds. 
Via The Motley Fool
This Low-Risk ETF Can Turn $39,000 Into $1 Million in 25 Years
Funneling money into this fund can drastically simplify your investing strategy. 
Via The Motley Fool
Rancho Biosciences Welcomes BenevolentAI as New Member to Its Single Cell Data Science Consortium
SAN DIEGO, February 1, 2023 (Newswire.com) - On Feb. 26, 2022, Rancho Biosciences, a leading data sciences services company, launched its Single Cell Data Science (SCDS) pre-competitive consortium,... 
Via Newswire.com
How Do Lawsuits Affect Johnson & Johnson's Stock Price?
JNJ's stock price was hit hard on Monday following the court's ruling for billions of dollars worth of lawsuits - what does this mean for investors? 
Via MarketBeat
Topics Bankruptcy Lawsuit
Exposures Financial Legal
3 Stocks You Can Confidently Buy in a Market Downturn
Investors can get a strong performance out of these stocks, even in a bear market. 
Via The Motley Fool
3 Warren Buffett Stocks to Buy Hand Over Fist in February
Three plain-as-day bargains are hiding in plain sight among Berkshire Hathaway's roughly four dozen holdings. 
Via The Motley Fool
Earnings Roundup: Tesla, Intel, Chevron, and More
Plus, Corrado Russo, head of global securities at Hazelview Investments, shares some insight for real estate investors. 
Via The Motley Fool
The 7 Best Climate Change Stocks to Buy for 2023
With environmental sustainability becoming an increasingly critical issue, these are the best climate change stocks to buy. 
Via InvestorPlace
Sony Scales Back PlayStation VR2 Output, Sam Bankman-Fried Attempted To Regain Control Of FTX, White House Plans To End COVID-19 Emergency: Today's Top Stories
Bloomberg 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.